Non-alcoholic fatty liver disease: A growing public health problem in Turkey

Kaya, Eda; YILMAZ, YUSUF

doi:10.5152/tjg.2019.18045

Non-alcoholic fatty liver disease: A growing public health problem in Turkey

Eda KAYA, (İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, İstanbul, Türkiye)

Yusuf YILMAZ (Marmara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, İstanbul, Türkiye)

Turkish Journal of Gastroenterology

15 1

Yıl: 2019 Cilt: 30 Sayı: 10 Sayfa Aralığı: 865 - 871 Metin Dili: İngilizce DOI: 10.5152/tjg.2019.18045 İndeks Tarihi: 16-07-2020

Non-alcoholic fatty liver disease: A growing public health problem in Turkey

Öz:

Non-alcoholic fatty liver disease (NAFLD) is histologically classified as either non-alcoholic fatty liver or non-alcoholic steatohepatitis(NASH). NASH is the progressive subtype of NAFLD. Individuals with NASH are at significant risk of developing hepatic fibrosis, cirrhosis,hepatocellular carcinoma, and liver-related and all-cause mortality. NAFLD is closely associated with obesity, type 2 diabetes mellitus(T2DM), metabolic syndrome, and cardiovascular events. Its prevalence is estimated to be above 30% in Turkey; and recent studies confirm this estimate. According to these studies, the prevalence of NAFLD in Turkey is between 48.3% and 60.1%. Currently, Turkey canbe considered a risky region in terms of NAFLD burden as it is the most obese country in Europe with an obesity prevalence of 32.1% according to the 2016 World Health Organization data. Moreover, along with the increasing prevalence of obesity and T2DM in Turkey, theburden of NAFLD is estimated to increase in the upcoming decade. Despite the growing burden, we lack well-designed systemic studiesthat investigate NAFLD and its marked histological severity. In this review, we present studies on the burden of NAFLD and NASH, thenatural history of NAFLD, and its association with other systemic diseases conducted with Turkish populations.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Chalasani N, Younossi Z, Lavine JE, et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-57. [CrossRef]
2. Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Hepatology 2019; 69: 2672-82. [CrossRef]
3. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol 2019; 17: 748-55. [CrossRef]
4. Available from: http://www.who.int/gho/ncd/risk_factors/overweight_obesity/obesity_adults/en/ Cited : 15.12.2018
5. Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol 2018; 10: 530-42. [CrossRef]
6. Celebi S, Ataseven H, Mengucuk E, Deveci SH, Acık Y, Bahcecioglu İH. Epidemic features of nonalcoholic fatty liver in urban community of Elazıg. Akademik Gastroenteroloji Dergisi 2006; 5: 41-6.
7. Kasapoglu B, Turkay C, Yalcin KS, Carlioglu A, Sozen M, Koktener A. Low vitamin D levels are associated wıth increased risk for fatty liver disease among non-obese adults. Clin Med 2013; 13: 576-9. [CrossRef]
8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84. [CrossRef]
9. Okur G, Karacaer Z. The prevalence of non-alcoholic fatty liver disease in healthy young persons. North Clin Istanb 2016; 3: 111-7. [CrossRef]
10. Kaya E, Demir D, Alahdab YO, Yilmaz Y. Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. Eur J Gastroenterol Hepatol 2016; 28: 1264-7. [CrossRef]
11. Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur J Gastroenterol Hepatol 2013; 25: 1330-4. [CrossRef]
12. Yilmaz Y, Yesil A, Gerin F, et al. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scand J Gastroenterol 2014; 49: 611-6. [CrossRef]
13. Sezgin O, Akpinar H, Ozer B, et al. Kapadokya Kohort Çalışması: Gastrointestinal hastalıkların ve Ultrasonografik Bulguların Görülme Sıklığı. 35. National Gastroenterology Congress. 2018 November 21- 25; Antalya, Turkey. SS-085.
14. Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of NAFLD and NASH. Mayo Clin Proc 2015; 90: 1233-46. [CrossRef]
15. Bahcecioglu IH, Koruk M, Yilmaz O, et al. Demographic and Clinicopathological Characteristics of Nonalcoholic Fatty Liver Disease in the East-Southeastern Anatolia Regions in Turkey. Med Princ Pract 2006; 15: 62-8. [CrossRef]
16. Akyuz U, Yesil A, Yilmaz Y. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scand J Gastroenterol 2015; 50: 341-6. [CrossRef]
17. Yılmaz Y, Kanı HT, Demirtaş CÖ, Kaya E, Sapmaz AF, Qutranji L, et al. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Turk J Gastroenterol 2019; DOI: 10.5152/ tjg.2019.19072.
18. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-93. [CrossRef]
19. Yüksel F, Türkkan D, Yüksel I, Kara S, Çelik N, Şamdancı ET. Fatty liver disease in an autopsy series of children and adolescents. Hippokratia 2012; 16: 61-5.
20. Tutar E, Akkelle BS, Kesici CB, et al. The correlation between histopathologic steatosis/fibrosis and various non-invasive imaging and blood fibrosis indicators in children with NAFLD. Journal of Pediatric Gastroenterology and Nutrition. 51. The European Society for Paediatric Gastroenterology Hepatology and Nutrition Congress. 2018 May 9-15; Geneva, Switzerland. 2018; 66(Suppl 2): 646.
21. Boyraz M, Hatipoğlu N, Sarı E, et al. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obes Res Clin Pract 2014; 8: e356-63. [CrossRef]
22. Akcam M, Boyaci A, Pirgon O, Koroglu M, Dundar BN. Importance of the liver ultrasound scores in pubertal obese children with nonalcoholic fatty liver disease. Clin Imaging 2013; 37: 504-8. [CrossRef]
23. Özhan B, Ersoy B, Özkol M, Kiremitci S, Ergin A. Waist to height ratio: a simple screening tool for nonalcoholic fatty liver disease in obese children. Turk J Pediatr 2016; 58: 518-23. [CrossRef]
24. Forlani G, Giorda C, Manti R, et al. The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. J Diabetes Res 2016; 2016: 2931985. [CrossRef]
25. Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis 2007; 11: 17-23. [CrossRef]
26. Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016; 65: 1096-108. [CrossRef]
27. World Health Organization 2016. Global Reports on DM 2016. (Cited: 30.12.2018) Available from: URL: http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=374E66F97140F1C37784E7DC40055EAC?sequence=1
28. Satman I, Yilmaz T, Sengül A, et al. Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002; 25: 1551-6. [CrossRef]
29. Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28: 169-80. [CrossRef]
30. Demir M, Deyneli O, Yılmaz Y. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. Turk J Gastroenterol 2019; 30: 266-70. [CrossRef]
31. Yilmaz Y, Senates E, Yesil A, Ergelen R, Colak Y. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. J Diabetes Complications 2014; 28: 328-31. [CrossRef]
32. Yilmaz Y. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome? World J Hepatol 2012; 4: 332-4. [CrossRef]
33. Uslusoy HS, Nak SG, Gülten M, Bıyıklı Z. Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. World J Gastroenterol 2009; 15: 1093-8. [CrossRef]
34. Yilmaz Y, Senates E, Ayyildiz T, et al. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest 2012; 42: 411-8. [CrossRef]
35. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73. [CrossRef]
36. Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens 2010; 23: 1183-9. [CrossRef]
37. Colak Y, Senates E, Yesil A, et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013; 43: 100-7. [CrossRef]
38. Senturk O, Kocaman O, Hulagu S, et al. Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. Intern Med J 2008; 38: 183-9. [CrossRef]
39. Sapmaz F, Uzman M, Basyigit S, et al. Steatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD. Medicine (Baltimore) 2016; 95: e3280. [CrossRef]
40. Ozturk K, Uygun A, Guler AK, et al. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. Atherosclerosis 2015; 240: 380-6. [CrossRef]
41. Oguz D, Unal HU, Eroglu H, Gulmez O, Cevik H, Altun A. Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease. Anatol J Cardiol 2016; 16: 974-9. [CrossRef]
42. Yilmaz Y, Kurt R, Yonal O, et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis 2010; 211: 182-6. [CrossRef]
43. Yilmaz Y, Kurt R, Gurdal A, et al. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis 2011; 217: 125-9. [CrossRef]
44. Ozveren O, Dogdu O, Sengul C, Cinar V, Eroglu E, Kucukdurmaz Z. Deterioration of heart rate recovery index in patients with non-alcoholic fatty liver disease (NAFLD). Med Sci Monit 2014; 20: 1539-43. [CrossRef]
45. Sunbul M, Kivrak T, Durmus E, et al. Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. Cardiovasc Ther 2015; 33: 294-9. [CrossRef]

APA	Kaya E, YILMAZ Y (2019). Non-alcoholic fatty liver disease: A growing public health problem in Turkey. , 865 - 871. 10.5152/tjg.2019.18045
Chicago	Kaya Eda,YILMAZ YUSUF Non-alcoholic fatty liver disease: A growing public health problem in Turkey. (2019): 865 - 871. 10.5152/tjg.2019.18045
MLA	Kaya Eda,YILMAZ YUSUF Non-alcoholic fatty liver disease: A growing public health problem in Turkey. , 2019, ss.865 - 871. 10.5152/tjg.2019.18045
AMA	Kaya E,YILMAZ Y Non-alcoholic fatty liver disease: A growing public health problem in Turkey. . 2019; 865 - 871. 10.5152/tjg.2019.18045
Vancouver	Kaya E,YILMAZ Y Non-alcoholic fatty liver disease: A growing public health problem in Turkey. . 2019; 865 - 871. 10.5152/tjg.2019.18045
IEEE	Kaya E,YILMAZ Y "Non-alcoholic fatty liver disease: A growing public health problem in Turkey." , ss.865 - 871, 2019. 10.5152/tjg.2019.18045
ISNAD	Kaya, Eda - YILMAZ, YUSUF. "Non-alcoholic fatty liver disease: A growing public health problem in Turkey". (2019), 865-871. https://doi.org/10.5152/tjg.2019.18045

APA	Kaya E, YILMAZ Y (2019). Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turkish Journal of Gastroenterology, 30(10), 865 - 871. 10.5152/tjg.2019.18045
Chicago	Kaya Eda,YILMAZ YUSUF Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turkish Journal of Gastroenterology 30, no.10 (2019): 865 - 871. 10.5152/tjg.2019.18045
MLA	Kaya Eda,YILMAZ YUSUF Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turkish Journal of Gastroenterology, vol.30, no.10, 2019, ss.865 - 871. 10.5152/tjg.2019.18045
AMA	Kaya E,YILMAZ Y Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turkish Journal of Gastroenterology. 2019; 30(10): 865 - 871. 10.5152/tjg.2019.18045
Vancouver	Kaya E,YILMAZ Y Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turkish Journal of Gastroenterology. 2019; 30(10): 865 - 871. 10.5152/tjg.2019.18045
IEEE	Kaya E,YILMAZ Y "Non-alcoholic fatty liver disease: A growing public health problem in Turkey." Turkish Journal of Gastroenterology, 30, ss.865 - 871, 2019. 10.5152/tjg.2019.18045
ISNAD	Kaya, Eda - YILMAZ, YUSUF. "Non-alcoholic fatty liver disease: A growing public health problem in Turkey". Turkish Journal of Gastroenterology 30/10 (2019), 865-871. https://doi.org/10.5152/tjg.2019.18045